Clinical Significance of Perioperative Minimal Residual Disease Detected by Circulating Tumor DNA in Patients With Lung Cancer With a Long Follow-up Data: An Exploratory Study
Introduction: Molecular residual disease detected by circulating tumor DNA (ctDNA) has been reported to be predictive of patients’ outcomes in various types of cancers after curative intent treatment. Nevertheless, additional detailed information regarding the association of longitudinal ctDNA detec...
Saved in:
Main Authors: | Shuta Ohara, MD, PhD, Kenichi Suda, MD, PhD, Sumedha Sudhaman, PhD, Akira Hamada, MD, PhD, Masato Chiba, MD, PhD, Masaki Shimoji, MD, PhD, Toshiki Takemoto, MD, PhD, Ekaterina Kalashnikova, PhD, Samantha K. Cheung, PhD, Michael Krainock, MD, PhD, Jordan Feeney, BS, Himanshu Sethi, MPH, Minetta C. Liu, MD, Junichi Soh, MD, PhD, Yasuhiro Tsutani, MD, PhD, Tetsuya Mitsudomi, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | JTO Clinical and Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364324001322 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma
by: Yuji Uehara, MD, et al.
Published: (2025-03-01) -
A Phase I/II Study of Ultra-Hypofractionated Carbon-ion Radiation therapy for Low- and Intermediate-Risk Localized Prostate Cancer
by: Noriyuki Okonogi, MD, PhD, et al.
Published: (2025-03-01) -
Placental Vascular Malperfusion in Pregnancies With Congenital Heart Disease
by: Nour Rahnama, MD, et al.
Published: (2025-03-01) -
Lumbosacral Plexopathy After Carbon-ion Radiation Therapy for Postoperative Pelvic Recurrence of Rectal Cancer: Subanalysis of a Prospective Observational Study (GUNMA 0801)
by: Takuya Kumazawa, MD, PhD, et al.
Published: (2025-03-01) -
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01)